

A Digital Appointment Reminder Tool For Long-Acting Injectable PrEP

Please refer to the adverse events reporting and prescribing information on the back of this document.

A simple appointment reminder tool designed to help individuals adhere to their long-acting PrEP injection appointments.

Digital reminders may support appointment adherence, reduce missed doses of PrEP and improve retention in PrEP care¹

Evidence suggests that digital reminder tools (such as apps, web portals) may reduce missed doses of PrEP and improve retention in PrEP care.¹

The digital appointment reminder tool works by sending automated reminders and follow-up messages to individuals about their upcoming injection appointments.



After individuals have received their first two injections, ask them to scan the QR code on the card.



Ask individuals to read the disclaimer and important information that appears on their screen.



Inform individuals of their target injection date and ask them to click on “Add reminders to calendar” followed by “Add all” for iPhones, or “Open” and “Save” for Android devices.



People will receive an appointment reminder seven days before their target injection date, and a follow-up message seven days after.



For the next twelve months, individuals will continue to receive reminders for their upcoming injection appointments.

✓ Provides support following the first two injections.

✓ For individuals who want additional support in managing their appointments without the worry of forgetting or missing a dose.

✓ To support HCPs with additional follow-up options for people receiving APRETUDE.

✓ Provides people receiving long-acting injectable PrEP with automated follow-up messages, and supports clinics with ways to assist with reminders.

APRETUDE[▼] (cabotegravir)

Indication: APRETUDE is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg²



For prescribing information and adverse events reporting information, please scan or click the QR code above

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for **MHRA Yellowcard** in the **Google Play** or **Apple App Store**. Adverse events should also be reported to GSK via the [GSK Reporting Tool](https://gsk.public.reportum.com/) at <https://gsk.public.reportum.com/> or on 0800 221441.

Abbreviations:

HCP: healthcare professional; **HIV:** human immunodeficiency virus; **MHRA:** medicines and healthcare products regulatory agency.

References:

1. Guide to Community Preventive Services. (2021). HIV Prevention: Digital Health Interventions to Improve Adherence to HIV Pre-Exposure Prophylaxis. Accessed January 2026 at <https://www.thecommunityguide.org/findings/hiv-prevention-digital-health-interventions-improve-adherence-hiv-pre-exposure-prophylaxis.html>
2. APRETUDE (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC).